SCHEDULE: Affinity Asset Advisors Discloses 9.99% Stake in iBio, Inc.

Affinity Asset Advisors, LLC and Michael Cho have reported beneficial ownership of 5,068,882 shares of iBio, Inc. common stock, representing 9.99% of the outstanding shares.

Summary

• Affinity Asset Advisors, LLC and Michael Cho (collectively, the 'Reporting Persons') have filed a Schedule 13G, indicating their beneficial ownership of 5,068,882 shares of iBio, Inc. common stock.
• This ownership stake represents approximately 9.99% of the company's outstanding common stock as of June 30, 2026.
• The shares are held by Affinity Healthcare Fund, LP, with Affinity Asset Advisors, LLC acting as the investment manager.
• Michael Cho, as the managing member of Affinity Asset Advisors, LLC, is also considered a beneficial owner.
• The reported ownership includes 1,061,001 shares issuable upon the exercise of warrants, subject to a 9.99% beneficial ownership limitation.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, primarily indicating a significant ownership stake without immediate strategic implications.

Positives

• Significant ownership stake of 9.99% by Affinity Asset Advisors and Michael Cho, indicating confidence or strategic interest in iBio, Inc.
• The ownership includes shares issuable from warrants, suggesting potential for further investment or a belief in the company's future value.

Negatives

• The filing does not provide details on the specific strategy or intentions behind this ownership stake.
• The beneficial ownership is capped at 9.99%, which may limit further direct accumulation of shares without triggering additional disclosure requirements.

Risks

• Potential for increased market volatility if the Reporting Persons decide to significantly alter their position.
• The 9.99% ownership limitation could lead to complex maneuvers if the Reporting Persons wish to increase their influence or stake beyond this threshold.

Future Outlook

The filing itself is a snapshot of current ownership and does not contain forward-looking statements or guidance from iBio, Inc. The future outlook for iBio, Inc. would be found in their separate SEC filings.

Management Comments

• "As of June 30, 2026, the Adviser and Mr. Cho (collectively, the 'Reporting Persons') beneficially own 5,068,882 shares of common stock, par value $0.001 per share ('Common Stock'), of iBio, Inc. (the 'Issuer'), which amount includes 1,061,001 shares of Common Stock issuable upon exercise of warrants (the 'Warrants')."
• "The Warrants are all subject to a beneficial ownership limitation of 9.99% of the number of shares of Common Stock of the Issuer outstanding immediately after giving effect to the issuance of the shares issuable upon exercise of the Warrants (the 'Beneficial Ownership Limitation')."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant stakeholders accumulating positions in publicly traded companies. iBio, Inc. operates in the biotechnology sector, which often sees active investment and strategic stake-building by specialized funds.

Stakeholder Impact

• Shareholders: May view the increased stake as a sign of investor confidence, potentially influencing market perception. However, without further information, the long-term impact is uncertain.
• Management of iBio, Inc.: May need to consider the influence of a significant shareholder, especially if the stake grows or if the investor becomes more activist.
• Creditors/Suppliers: No direct impact indicated by this filing.

Next Steps

• Affinity Asset Advisors, LLC and Michael Cho will continue to hold their shares in iBio, Inc.
• Any future changes in ownership exceeding the 5% threshold will require new filings.
• iBio, Inc. will continue its operations and report its financial and operational results in subsequent filings.

Key Dates

Keywords

iBio, Inc., Schedule 13G, Affinity Asset Advisors, Michael Cho, Beneficial Ownership, Common Stock, Warrants, Investment Management